Author
Ambrogio Orlando
Other affiliations: University of Verona, University of Messina
Bio: Ambrogio Orlando is an academic researcher from University of Palermo. The author has contributed to research in topics: Inflammatory bowel disease & Ulcerative colitis. The author has an hindex of 38, co-authored 177 publications receiving 6107 citations. Previous affiliations of Ambrogio Orlando include University of Verona & University of Messina.
Papers published on a yearly basis
Papers
More filters
TL;DR: In patients with unresectable HCC, chemoembolization significantly improved the overall 2-year survival compared with nonactive treatment, but the magnitude of the benefit is relatively small.
Abstract: PURPOSE: To review the available evidence of chemoembolization for unresectable hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Computerized bibliographic searches with MEDLINE and CANCERLIT databases from 1980 through 2000 were supplemented with manual searches, with the keywords “hepatocellular carcinoma,” “liver cell carcinoma,” “randomized controlled trial [RCT],” and “chemoembolization.” Studies were included if patients with unresectable HCC were enrolled and if they were RCTs in which chemoembolization was compared with nonactive treatment (five RCTs) or if different transarterial modalities of therapy (13 RCTs) were compared. Data were extracted from each RCT according to the intention-to-treat method. Five of the RCTs with a nonactive treatment arm were combined by using the random-effects model, whereas all 18 RCTs were pooled from meta–regression analysis. RESULTS: Chemoembolization significantly reduced the overall 2-year mortality rate (odds ratio, 0.54; 95% CI: 0.33, 0.89; P = .015) c...
772 citations
TL;DR: The role of smoking as an independent predictor of clinical, surgical, and endoscopic recurrence in Crohn's disease is evaluated.
422 citations
TL;DR: It was found that study participants with Crohn's disease who received mongersen had significantly higher rates of remission and clinical response than those who received placebo.
Abstract: BackgroundCrohn’s disease–related inflammation is characterized by reduced activity of the immunosuppressive cytokine transforming growth factor β1 (TGF-β1) due to high levels of SMAD7, an inhibitor of TGF-β1 signaling. Preclinical studies and a phase 1 study have shown that an oral SMAD7 antisense oligonucleotide, mongersen, targets ileal and colonic SMAD7. MethodsIn a double-blind, placebo-controlled, phase 2 trial, we evaluated the efficacy of mongersen for the treatment of persons with active Crohn’s disease. Patients were randomly assigned to receive 10, 40, or 160 mg of mongersen or placebo per day for 2 weeks. The primary outcomes were clinical remission at day 15, defined as a Crohn’s Disease Activity Index (CDAI) score of less than 150, with maintenance of remission for at least 2 weeks, and the safety of mongersen treatment. A secondary outcome was clinical response (defined as a reduction of 100 points or more in the CDAI score) at day 28. ResultsThe proportions of patients who reached the prim...
364 citations
TL;DR: Patients older than 65 years treated with TNF inhibitors for IBD have a high rate of severe infections and mortality compared with younger patients or patients of the same age that did not receive these therapeutics.
303 citations
TL;DR: Rectal biopsy should always be performed in severe steroid-resistant colitis, as cytomegalovirus infection is a frequent cause of severe refractory colitis.
246 citations
Cited by
More filters
TL;DR: The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.
7,851 citations
[...]
01 Feb 2009
TL;DR: This Secret History documentary follows experts as they pick through the evidence and reveal why the plague killed on such a scale, and what might be coming next.
Abstract: Secret History: Return of the Black Death Channel 4, 7-8pm In 1348 the Black Death swept through London, killing people within days of the appearance of their first symptoms. Exactly how many died, and why, has long been a mystery. This Secret History documentary follows experts as they pick through the evidence and reveal why the plague killed on such a scale. And they ask, what might be coming next?
5,234 citations
TL;DR: Although there are few epidemiologic data from developing countries, the incidence and prevalence of IBD are increasing with time and in different regions around the world, indicating its emergence as a global disease.
4,096 citations
Journal Article•
3,097 citations
TL;DR: Chemoembolization improves survival of patients with unresectable HCC and may become the standard treatment and only low‐quality scale trials suggested 1‐year improvement in survival.
2,794 citations